Merz Accelerates APAC Expansion: "Natural Fillers with Multi-Density Adherence"

Merz Aesthetics (Merz) announced on January 14 that it has selected actress Song Hye-kyo as the regional ambassador for its hyaluronic acid filler 'Belotero' and will be accelerating its efforts to target the Asia-Pacific (APAC) market. On this day, Merz held a launch event for the new APAC campaign for 'Belotero,' titled 'Nature Lies in the Details,' at The Westin Seoul Parnas in Gangnam-gu, Seoul, and made this announcement. The campaign highlights the technology that enables the product to adhere closely to the skin, allowing individuals to realize their own natural beauty. Belotero is composed of four lines: Balance, Soft, Intense, and Volume. It is designed to allow for customized procedures tailored to the unique characteristics of each individual's skin. The product achieves a balance of cohesiveness, elasticity, and moldability, providing natural wrinkle improvement and volume restoration. Its patented CPM (Cohesive Polydensified Matrix) technology ensures natural-looking resul

Bio Health

01.14 18:07

Cha Biotech to Raise 10 Billion Won Through Capital Increase... Third-Party Allotment to LG CNS

Cha Biotech announced on January 14 that it has decided to conduct a third-party allotment capital increase to raise approximately 10 billion won in operating funds. A total of 771,664 new common shares will be issued at 12,959 won per share. The third-party allotment recipient is LG CNS Co., Ltd.

Bio Health

01.14 17:56

"How Should Telemedicine Platform Regulations Be Set?"... Joint Meeting of Health and SMEs Ministries

Lee Hyunhoon, Second Vice Minister of the Ministry of Health and Welfare, and Noh Yongseok, First Vice Minister of the Ministry of SMEs and Startups, held a joint meeting between the Ministry of Health and Welfare and the Ministry of SMEs and Startups on the 14th to discuss the amendment to the Pharmaceutical Affairs Act and listened to the opinions of the healthcare sector and the telemedicine platform industry. The meeting was organized to hear the positions of stakeholders regarding the amendment to the Pharmaceutical Affairs Act, which seeks to restrict telemedicine platforms from also operating as pharmaceutical wholesalers. The event was attended by representatives from pharmaceutical organizations such as the Korea Alliance of Patients Organization, the Korean Health and Medical Workers' Union, the Korean Pharmaceutical Association, and the Korean Medical Association, as well as from the telemedicine industry including the Korea Telemedicine Industry Council, the Korea Digital H

Bio Health

01.14 15:34

Yuhan Launches New Advertising Campaign for Cold Medicine "Contact Cold"

Yuhan Corporation announced on January 14 that it will launch a new advertising campaign for its cold medicine brand 'Contact Cold' starting this month. This campaign features comedian Hwang Jesung as the model. The campaign's message, "When you think you've caught a cold, Contact Cold," captures the moment when one feels the onset of a cold. The advertisements will be aired across a variety of media, including TV, radio, digital platforms, and outdoor billboards. Contact Cold is a cold medicine effective for nasal congestion caused by the common cold (acute rhinitis), allergic rhinitis, and sinusitis, as well as for symptoms such as runny nose, sneezing, watery eyes, sore throat, and a heavy head. The improved model replaces the previous phenylephrine hydrochloride ingredient with pseudoephedrine.

Bio Health

01.14 14:01

Yuhan Corporation Aims for 30% Shareholder Return Rate by 2027

Yuhan Corporation is continuing its shareholder return policy aimed at enhancing shareholder value. According to Yuhan Corporation on January 14, the company plans to achieve an average shareholder return rate of over 30% from 2025 to 2027. To this end, the company will retire 1% of its treasury shares by 2027 and will continue to increase its dividend per share. Currently, Yuhan Corporation’s dividend payout ratio stands at 53%, which is significantly higher than the industry average of around 10%. As of last year, the company’s total dividend payout was in the 30 billion won range. It paid 500 won per common share and 510 won per preferred share. Interest in Yuhan Corporation’s dividend policy has recently increased considerably. This is due to the spotlight on the efficacy of the combination therapy of the new lung cancer drug Leclaza (ingredient: lazertinib) and Johnson & Johnson’s Rybrevant (ingredient: amivantamab). The Leclaza combination therapy was listed as the preferred regi

Bio Health

01.14 14:00

Daewoong Pharmaceutical Applies for Approval of Korea's First JAK3 Inhibitor New Drug for Canine Atopic Dermatitis

Daewoong Pharmaceutical announced on January 14 that it had applied for product approval for an atopic dermatitis treatment for dogs containing the active ingredient 'flodicitinib' to the Animal and Plant Quarantine Agency on December 24. This product is an example of Daewoong Pharmaceutical developing its independently discovered small-molecule new drug substance, 'flodicitinib,' into a veterinary medicine exclusively for companion animals. Its safety and efficacy have been verified through non-clinical and clinical studies that meet international standards. Flodicitinib is the first JAK inhibitor-based atopic dermatitis treatment for dogs developed in Korea. After completing Phase 2 clinical trials in 2023, the company entered Phase 3 the following year and successfully concluded Phase 3 at the end of last year. Currently, a Phase 1 clinical trial for a human medicine using the same ingredient is also underway. JAK inhibitors are treatments that alleviate itching and skin inflammatio

Bio Health

01.14 11:16

Chongkundang's Dupixent Biosimilar Receives First Phase 1 Clinical Trial Approval in Europe

Chongkundang announced on January 14 that its biosimilar of Dupixent (ingredient name: dupilumab), 'CKD-706,' has received the first-ever Phase 1 clinical trial approval in Europe. This approval was granted simultaneously by the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).The clinical trial will demonstrate the pharmacokinetic equivalence between CKD-706 and Dupixent in healthy European adults, and will also compare their pharmacodynamics, safety, and immunogenicity. Dupilumab is a biopharmaceutical developed using recombinant DNA technology to mirror the structure of human antibodies. It works by binding to the receptor (IL-4Rα) commonly used by the immune modulators interleukin (IL)-4 and interleukin (IL)-13, which are involved in type 2 inflammatory responses, thereby inhibiting their signaling pathways. The U.S. Food and Drug Administration (FDA) has approved it for eight indications, including atopic dermatitis, asthma, chr

Bio Health

01.14 09:56

Samsung Bioepis Receives Domestic Approval for Epzutek Pen Formulation

Samsung Bioepis announced on January 14 that it has received product approval from the Ministry of Food and Drug Safety for the pre-filled pen (PFP) formulation of its autoimmune disease treatment, Epzutek (ingredient: ustekinumab). This approval marks the first case in Korea where a pen-type formulation of a ustekinumab-based drug, including the original product, has been developed and authorized by the Ministry of Food and Drug Safety, as opposed to the conventional pre-filled syringe (PFS) format. The pen formulation is designed to allow patients to administer the medication more easily and accurately, offering advantages in terms of convenience for self-injection. Epzutek is a biosimilar to Stelara. Stelara, developed by Janssen, is a treatment for autoimmune diseases such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, with annual global sales reaching approximately 15 trillion won (10.361 billion dollars). Jung Byungin, Head of the Regulatory Af

Bio Health

01.14 08:33

Yonsei Medical Center Successfully Concludes "2026 Yonsei Digital Health Symposium"

Merz Accelerates APAC Expansion: "Natural Fillers with Multi-Density Adherence"

Cha Biotech to Raise 10 Billion Won Through Capital Increase... Third-Party Allotment to LG CNS

"How Should Telemedicine Platform Regulations Be Set?"... Joint Meeting of Health and SMEs Ministries

Yuhan Launches New Advertising Campaign for Cold Medicine "Contact Cold"

Yuhan Corporation Aims for 30% Shareholder Return Rate by 2027

Daewoong Pharmaceutical Applies for Approval of Korea's First JAK3 Inhibitor New Drug for Canine Atopic Dermatitis

Chongkundang's Dupixent Biosimilar Receives First Phase 1 Clinical Trial Approval in Europe

Samsung Bioepis Receives Domestic Approval for Epzutek Pen Formulation

Special Coverage

In the News